High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection

Detalles Bibliográficos
Autores principales: Chow, Shien, Evans, Manon, Galvis, Victoria, Leach, Rebecca, Keene, Elizabeth, Chan, Kevin, Spencer-Shaw, Andrea, Jonathan, Shanks, Shabalak, Alaaeldin, Thistlethwaite, Fiona, Hawkins, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288767/
http://dx.doi.org/10.1186/2051-1426-2-S3-P89

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288767/
http://dx.doi.org/10.1186/2051-1426-2-S3-P89

Ejemplares similares